Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 20, 2020
Daily News
April 20, 2020
- Novartis’ Entresto, Mayzent Up for MHLW Panel Review in Round Robin Method
April 20, 2020
- Japan Generic Makers’ New Grad Hiring Logs 1st Increase Since FY2016
April 20, 2020
- Some Drug Makers Rejuvenating Workforce by Boosting New Hires after Job Cuts: Jiho Survey
April 20, 2020
- Towa, Osaka Psychiatric Medical Center Pair Up on Novel Biomarker Research for AD
April 20, 2020
- Konica Minolta’s US Subsidiary to Launch PCR Testing Platform
April 20, 2020
- Takeda, Tohoku University Ink Joint Research Pact on Whole Genome Sequencing
April 20, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…